A phase I study of OSE-172 for the treatment of cancer

Trial Profile

A phase I study of OSE-172 for the treatment of cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs OSE-172 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Mar 2018 According to an OSE Immunotherapeutics media release, company received a 9.2 million Euro grant from Bpifrance in July as part of a collaborative program (EFFI-CLIN) to support the development of OSE-172.
    • 28 Mar 2018 According to an OSE Immunotherapeutics media release, company expects to start clinical phase within the next few months.
    • 08 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top